Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 8/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433791 | 0.87 | NPC1 (0.58) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL29475123 | 0.83 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL7208136 | 0.83 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL16465542 | 0.82 | NPC1 (0.97) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL16627058 | 0.81 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL31081137 | 0.81 | KDM4E (0.72) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL721792 | 0.81 | KDM4E (0.72) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL9269321 | 0.81 | GRIK1 (0.56) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL8769590 | 0.81 | NPC1 (0.82) | NPC1RAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL10562380 | 0.80 | NPC1 (0.66) | NPC1RAB9ALMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| EP-1776340-B1 | N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | IDO1, IDO2, NPY5R | NPC1 930/4885RAB9A 2211/4885LMNA 986/4885 |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | NPY5R, TPH2, TPH1 | NPC1 1114/4885RAB9A 2457/4885LMNA 1737/4885 |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | NPY5R, TPH2, TPH1 | NPC1 1114/4885RAB9A 2457/4885LMNA 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.